Rituximab‐induced serum sickness in refractory immune thrombocytopenic purpura
Serum sickness may occur in patients treated with chimeric monoclonal antibody. Rituximab, an anti‐CD20 chimeric monoclonal antibody, is used with increasing frequency in chronic immune thrombocytopenic purpura (ITP). Rituximab is relatively safe; however, serum sickness is reported
in 1‐20% of patients, more commonly among those with autoimmune conditions. We describe a case of serum sickness in a patient with ITP and review the literature of rituximab‐induced serum sickness.